87591-74-0

Usage

Uses

Used in Pharmaceutical Industry:
2-(CHLOROMETHYL)-6-METHYL-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE is used as a building block in organic synthesis for the development of new pharmaceuticals. Its unique structure and potential pharmacological activity make it a promising candidate for the creation of novel drugs with potential therapeutic applications.
Used in Medicinal Chemistry Research:
2-(CHLOROMETHYL)-6-METHYL-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE is used as a valuable target for further research and development in the field of medicinal chemistry. Its specific biological and chemical properties allow researchers to explore its potential applications in the discovery and design of new therapeutic agents.

InChI:InChI=1/C10H9ClN2O/c1-7-3-2-4-9-12-8(6-11)5-10(14)13(7)9/h2-5H,6H2,1H3

Upstream product

• 1824-81-3 2-Amino-6-methylpyridine 
• 638-07-3 ethyl (2-chloroaceto)acetate 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 1434288-24-0 2-(1H-benzimidazol-1-ylmethyl)-6-methyl-4H-pyrido[1,2-a]pyrimidin-4-one 

Relevant academic research and scientific papers

PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR

The present invention discloses a series of pyrazolopyrimidine derivatives and use thereof in preparing a medicament for treating a disease related to PI3K, and in particular, discloses a derivative compound of formula (I), a tautomer thereof or a pharmaceutically acceptable composition thereof.

AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF

Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Synthesis of some substituted pyrido[1,2-a]pyrimidin-4-ones and 1,8-naphthyridines

The substituted 4H-pyrido[1,2-a]pyrimidin-4-ones (I) were obtained by the condensation of substituted 2-aminopyridines with β-ketocarboxylic esters in PPA. Some of the derivatives I were transformed into the corresponding 1,8-naphthyridines II and III.